Daewon Pharmaceutical Co., Ltd. (KRX:003220)

South Korea · Delayed Price · Currency is KRW

8,160.00

+370.00 (4.75%)

At close: Aug 7, 2026

-37.71% (1Y)

Market Cap	174.90B -37.7%
Revenue (ttm)	605.66B +1.3%
Net Income	-4.38B
EPS	-224.86
Shares Out	21.43M
PE Ratio	n/a
Forward PE	7.78
Dividend	250.00 (3.06%)
Ex-Dividend Date	Dec 29, 2025

Volume	35,004
Open	7,870.00
Previous Close	7,790.00
Day's Range	7,830.00 - 8,160.00
52-Week Range	7,060.00 - 13,670.00
Beta	0.14
Analysts	Strong Buy
Price Target	14,666.67 (+79.74%)
Earnings Date	Aug 13, 2026

About Daewon Pharmaceutical

Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company’s principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a t... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1958

Employees 1,283

Stock Exchange Korea Stock Exchange

Ticker Symbol 003220

Full Company Profile

Financial Performance

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for 003220 stock is "Strong Buy." The 12-month stock price target is ₩14,667, which is an increase of 79.74% from the latest price.

Price Target

₩14,667

(79.74% upside)

Analyst Consensus: Strong Buy

Stock Forecasts